First use for Imbruvica outside blood cancer.
Expert panel concerned about safety of sirukumab.
Regulators concerned over liver damage risk
Upadacitinib hopes drug will reduce reliance on Humira.
New drug will be sold at around 30% discount to rivals.
AbbVie’s hepatitis C drug granted early access in UK
Trial backs patient-friendly regime in tough to treat strain.
Veliparib fails in two phase 3 trials.